Emerging Infections
Announcements
The COVID-19 pandemic is a serious public health threat that continues to permeate all populations and sectors in the country, and the job sector is no exception. To protect the welfare of the Filipino workforce, the Department of Health (DOH), Department of Labor and Employment (DOLE), Department of Trade and Industry (DTI) together with the World Health Organization (WHO) and stakeholders from the different medical societies in the Philippines issue this handbook, which compiles essential information based on important issuances on COVID-19 prevention and management in the workplace. This hopes to provide proper guidance and appropriate information to all Occupational Safety and Health (OSH) Committees and other key stakeholders to empower them in ensuring that Filipino employees and workers everywhere in the country know how to protect themselves, their colleagues, and families from the threat of COVID-19.
Version 1 as of September 2020. This handbook will be updated as we compile the most recent evidence and policies relative to the workplace, as the COVID-19 pandemic progresses.
You may download the Workplace Handbook on COVID-19 Management and Prevention here.
Workplace Handbook -Version 1 _ Sept. 30-
Emerging Infections
For any questions or information, please email: covidrapidreviewteam@gmail.com.
Emerging Infections
For any questions or information, please email: covidrapidreviewteam@gmail.com.
CP Abridged 29 Aug 2020 RGM
Emerging Infections
For any questions or information, please email: covidrapidreviewteam@gmail.com.
AsymptomaticPedia Abridged 04 Aug 2020 FCT
Emerging Infections
For any questions or information, please email covidrapidreviewteam@gmail.com.
ECLIA 20200823_180625
Emerging Infections
For any questions or information, please email: covidrapidreviewteam@gmail.com.
RAgT_SR_22Aug2020_V4 Final
Rapid Review
For any questions or information, please email covidrapidreviewteam@gmail.com.
Facemask pedia Abridged 15June
Info-graphics
Announcements
> NOTE: The COVID-19 Living Clinical Practice Guidelines contains UPDATED recommendations and evidence summaries. Click here to be redirected to the COVID LCPG.
This Interim Guidance on the Clinical Management of Adult Patients with Suspected or Confirmed COVID-19 Infection (Version 3.1) is an update of the March 31, 2020 guidelines released by the Philippine Society for Microbiology and Infectious Diseases. New evidence have been published since then necessitating this update.This document is written to guide clinicians and health care workers in their COVID-19 related management decisions. It is based on available scientific evidence that is also rapidly evolving, as more is discovered about the pathophysiology of SARS CoV-2 and the pathogenesis of the disease. As such, the recommendations in this guideline are based on limited, often low-quality evidence, and need to be carefully balanced with clinical judgment. The use of investigational drugs should be discussed with the patient or a legally authorized representative carefully outlining the potential adverse reactions and the potential clinical benefits of these investigational drugs. A signed informed consent should be obtained by the clinician.
DOWNLOAD the Interim Management Guidelines for COVID-19 (Version 3.1) here.
The Philippine Society for Microbiology and Infectious Diseases (PSMID) Guidance on the Management of Mpox, Ver. 1 provides the basic and most updated information on management of patients confirmed with mpox.
This guidance complements the mpox recommendations of the DOH (Updated Interim Guidelines on the Prevention, Detection, and Management of MPOX, by Department of Health, August 26, 2024, Department Memorandum 2024-0306) and PHICS-PHICNA (Interim Guidelines on the Prevention and Control of Monkeypox version 1).
The antivirals, immunoglobulin and vaccines discussed below are not available locally. In our local situation, we should maximize supportive care for mpox cases.
